醋酸亮丙瑞林可变剂量用于性早熟的重要性：可接受的抑制范围
Importance of leuprolide acetate variable dosing for precocious puberty: a range of acceptable suppression.
作者信息
Cohen Daniela, Janfaza Mona, Klein Karen O
机构信息
Division of Pediatric Endocrinology, Rady Children's Hospital San Diego, Department of Pediatrics, Division of Pediatric Endocrinology, University of California San Diego, San Diego, CA 92123, USA.
出版信息
J Pediatr Endocrinol Metab. 2009 Jul;22(7):629-34. doi: 10.1515/jpem.2009.22.7.629.
AIM
The effect of the variation in hormonal suppression on bone maturation, growth velocity, and adult height prediction was examined during treatment with leuprolide acetate for central precocious puberty (CPP).
METHODS
Ten girls on variable doses of Lupron were studied for one year. Height, weight, body mass index, luteinizing hormone (LH), estradiol, and growth velocity were measured every 3 months. Bone age and predicted height were assessed every 6 months.
RESULTS
LH range changed from 0.5-1.4 IU/I to 0.1-2.8 IU/I. The average Lupron dose decreased from 0.33 +/- 0.11 to 0.26 +/- 0.08 mg/kg. Predicted adult height averaged 158.33 +/- 9.5cm at the start of the study and increased to 161.45 +/- 6.26 cm (p <0.01). LH and estradiol did not correlate with the rate of bone maturation, growth velocity, predicted height, or with leuprolide dose.
CONCLUSION
Variable dosing of leuprolide acetate is needed to achieve similar amounts of hormonal suppression, yet small changes in dose did not significantly change LH or estradiol levels or predicted height.
目的
在醋酸亮丙瑞林治疗中枢性性早熟（CPP）期间，研究激素抑制变化对骨成熟、生长速度和成年身高预测的影响。
方法
对10名使用不同剂量Lupron的女孩进行了为期一年的研究。每3个月测量身高、体重、体重指数、促黄体生成素（LH）、雌二醇和生长速度。每6个月评估骨龄和预测身高。
结果
LH范围从0.5 - 1.4 IU/I变为0.1 - 2.8 IU/I。Lupron平均剂量从0.33±0.11降至0.26±0.08 mg/kg。研究开始时预测成年身高平均为158.33±9.5cm，增加到161.45±6.26 cm（p<0.01）。LH和雌二醇与骨成熟率、生长速度、预测身高或亮丙瑞林剂量均无相关性。
结论
需要采用可变剂量的醋酸亮丙瑞林来实现相似程度的激素抑制，然而剂量的微小变化并未显著改变LH或雌二醇水平或预测身高。
Zotero 插件